ELTX · Elicio Therapeutics
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Market Cap
42.46M
52 Wk Range
$1.25 - $16.00
Previous Close
$1.50
Open
$1.47
Volume
113,404
Day Range
$1.44 - $1.59
Enterprise Value
25.55M
Cash
30.9M
Avg Qtr Burn
-10.36M
Insider Ownership
25.07%
Institutional Own.
27.10%
Qtr Updated
Sep 30th 2026
